欢迎访问本站!

首页体育正文

aws试用账号(www.2km.me)_Declare Covid endemic only when multivalent vaccines are available

admin2021-10-2729

aws试用账号

aws试用账号www.2km.me)提供aws账号、aws全区号、aws32v账号、亚马逊云账号出售,提供api ,质量稳定,数量持续。另有售azure oracle linode等账号.

THE surge in confirmed Covid-19 cases and deaths in Singapore after its declaration of “living with Covid” strategy should serve as an example to all other Southeast Asian countries, including Malaysia, that it is premature to declare Covid-19 an endemic. 

There is a need to move ahead of the epidemic as we know more about the virus.

A more effective vaccination programme is needed including more flexible implementation of a third booster dose vaccination programme and embark on a children vaccination campaign in order to get more than 90% of the total population immunised by the end of 2021.

The Ministry of Health (MOH) should also announce the daily inoculation numbers and rates for adolescents and children below 17 years of age. 

The European countries, Canada, the UK and the US have a proven effective and approved heterologous prime boost strategy to combat and contain new variants.

Diversification of vaccine sources and supply to making heterologous prime boost more flexible will speed up the containment of the epidemic to the endemic phase. 

There are also concerns from the public regarding MOH’s delay in moving the third dose booster campaign especially among the vulnerable senior citizens, public servants and health care workers. 

MOH is urged to announce the research data and findings on the benefits of heterologous and homologous prime boost.

So far, the Institute of Clinical Research has not officially announced its peer-reviewed data on the matter. 

There are three Covid-19 vaccines available locally including Sinovac’s CoronaVac, Pfizer’s Cominarty and Astra Zeneca’s Vaxzevria.

So far, MOH has only approved the mix-and-match regime that is a third dose with Comirnaty after two doses of CoronaVac.

Nonetheless there has been no specific data released on the efficacy and safety profile of the said regime. 

Data on other mixed combinations of vaccine booster should be released too, including that of Pfizer followed by Sinovac as the third dose booster; Astra Zeneca followed by Pfizer or Sinovac; and Sinovac followed by Astra Zeneca respectively. 

Proven efficacy with more diverse mixed combinations of vaccines allow more flexibility in administering the booster dose and achieving herd immunity to turn the current epidemic into an endemic stage. 

Malaysia has to continue enforcing public health measures and vigilance. We can more safely implement plans for the endemic phase only after multivalent vaccines are available, which is predicted to be available the earliest by the middle of 2022. 

There are already a few teams researching multivalent vaccines. MOH should seriously look into it, including getting locally based data on their efficacy at an early stage in order to make early procurements and implementation of vaccination programs next year before declaring the move into an endemic phase. – October 26, 2021.

网友评论